The strong Cohort C data de-risks TSC-101's manufacturing and efficacy profile ahead of the Phase 3 ALLOHA-2 trial initiation. Monitor for enrollment updates and subsequent Cohort C data readouts over the next 12-18 months, which will provide further validation of the commercial-ready process and support the pivotal trial.
Price Chart
Executive Summary
TScan Therapeutics reported positive initial data from Cohort C of the ALLOHA Phase 1 study for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with a 93% response rate and a ~90% manufacturing success rate using the commercial-ready process. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, de-risking the program and supporting advancement toward a registrational trial.
Key Facts
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- 93% of patients (13/14) responded with decreasing recipient chimerism
- ~90% manufacturing success rate (17/19) with commercial-ready process
- Safety profile consistent with Cohort A; no new safety signals
- Company to enroll first patient in Phase 3 ALLOHA-2 study in June 2026
- $128.1M cash as of March 31, 2026, funding operations into H2 2027
Financial Impact
No financial data provided; clinical-stage biotech with $128.1M cash runway into H2 2027
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 results
- Competition from other relapse-prevention therapies in post-transplant setting
- Need for additional financing beyond H2 2027 to complete Phase 3 and potential commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-276693 |
| Document: d103234d8k.htm | 0001193125-26-276693 |
| Document: d103234dex991.htm | 0001193125-26-276693 |
| Document: 0001193125-26-276693-index-headers.html | 0001193125-26-276693 |
| Document: 0001193125-26-276693-index.html | 0001193125-26-276693 |
| Document: 0001193125-26-276693.txt | 0001193125-26-276693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $0.3204 $0.3119 | ▼ −2.65% | ▼ −2.43% | $0.3189 (−0.47%) |
Sep 2, 2026 4w ago | 8-K | $0.3810 $0.3179 | ▲ +16.56% | ▲ +15.60% | $0.3189 (+16.30%) |
Aug 18, 2026 6w ago | 8-K | $0.7500 $0.7774 | ▼ −3.65% | ▼ −4.04% | $0.3189 (+57.48%) |
Aug 12, 2026 7w ago | 8-K | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3189 (+58.75%) |
Aug 12, 2026 7w ago | Press Release | $0.7730 $0.7500 | ▲ +2.98% | ▲ +2.53% | $0.3189 (+58.75%) |
Jun 22, 2026 14w ago | 8-K | $0.8651 $0.9775 | ▲ +12.99% | ▲ +13.45% | $0.3189 (−63.14%) |
Jun 22, 2026 14w ago | Press Release | $0.8651 $0.9688 | ▲ +11.99% | ▲ +14.06% | $0.3189 (−63.14%) |
May 6, 2026 21w ago | 8-K | $1.25 $1.15 | ▼ −8.00% | ▼ −9.13% | $0.3189 (−74.49%) |
Apr 2, 2026 26w ago | 8-K | $1.01 $1.05 | ▲ +3.96% | ▲ +0.34% | $0.3189 (−68.43%) |
Mar 4, 2026 30w ago | Press Release | $1.08 $1.15 | ▲ +6.48% | ▲ +7.81% | $0.3189 (−70.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access